Nalu Medical Releases “Haleakalā” Update, Extending Pulse Width Range and Unlocking the System’s Patient Activity Monitor

Nalu Medical announces the “Haleakalā” update, significantly updating the software and firmware of its award-winning Nalu Neurostimulation System.

CARLSBAD, Calif., February 24, 2022 /PRNewswire-PRWeb/ — Nalu Medical (“NALU”) announces the “Haleakalā” update, significantly updating the software and firmware of its award-winning Nalu Neurostimulation System. This update adds important new features for Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS).

The update expands the pacing pulse width setting to the widest range currently available in implantable SCS and PNS systems, up to 2000 microseconds. The Nalu Neurostimulation System is optimized to use this power-hungry setting with its portable external battery. This means healthcare teams can schedule Nalu patients for their exact therapy needs without worrying about depleting an implantable battery or accelerating the need for battery replacement surgery.

“Each patient’s pain is unique and having the ability to prescribe a wide range of stimulation options is important,” said Robert M. LevyMD, PhD from the Neuromodulation Institute of Boca Raton, Florida. “Stimulation pulse-width modulation has the potential to selectively recruit particular nerve fibers that could benefit patients with difficult-to-treat pain. intractable chronic pain.

The update also unlocks Activity Monitor 1.0, a patient activity monitoring capability that uses sensors built into the system’s therapy disc and stores a 30-day activity history viewable by healthcare teams and the patients.*

dr. Aaron Calodney from Precision Spine Care in Tyler, TX and former president of the American Society of Interventional Pain Physicians explains why this matters. “Activity monitoring reveals objective, measurable activity changes associated with patients’ daily living away from the clinic, increasing pain scores and self-reported activity changes. This can help disease management teams pain to understand the impact of therapies beyond the pain score.”

Like a smartphone operating system, the Nalu Neurostimulation System can be updated with a simple download, allowing existing patients as well as new patients to benefit from current and future enhancements to Nalu technology.

According to Count FenderCEO of Nalu, “We recognize that chronic pain is an ever-evolving condition for patients, and therefore healthcare teams need an ever-evolving toolkit of treatment options and tools. information. This update is in line with our commitment to continuously provide patients with the latest technology and innovation. This is another significant upgrade to our award-winning Nalu Neurostimulation System that not only benefits new patients , but retroactively gives existing patients access to our latest technical developments.

*Any interpretations made from this information are not intended to replace traditional methods of diagnosis or treatment. The healthcare provider is not expected to interpret or take clinical action based on this result. This is for information only.

About Nalu Medical

Nalu is a Carlsbad, Californiaspecializing in the development and commercialization of innovative and minimally invasive solutions for patients suffering from chronic neuropathic pain. The Nalu Neurostimulation System delivers gentle electrical impulses to the nervous system to modulate pain signals to the brain. The Nalu System was designed to address key unmet needs in the treatment of chronic neuropathic pain and provide a differentiated value proposition for patients and physicians.

About the Nalu Neurostimulation System

The Nalu System consists of a miniaturized, battery-free, fully-featured implantable pulse generator (IPG), wirelessly powered by an externally worn therapy disc and controlled via a smartphone remote control app. Despite its small size, Nalu’s micro-IPG offers similar processing capabilities to larger IPGs along with unique benefits associated with advanced waveforms, extensive programming options, exceptional scalability and expected life 18 years old. The Nalu Neurostimulation System is currently FDA cleared for Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications. To learn more, visit http://nalumed.com.

Indications for use

Spinal Cord Stimulation – The Nalu SCS System is indicated as a sole mitigating agent or as an adjunct to other modes of therapy used in a multidisciplinary approach for chronic and intractable trunk and/or extremity pain, including unilateral pain or bilateral. Trial devices are only used for trial stimulation (≤ 30 days) to determine effectiveness before recommending a permanent (long-term) device.

Peripheral Nerve Stimulation – The Nalu PNS System is indicated for the management of pain in adults with chronic severe and refractory pain of peripheral nerve origin, either as a sole mitigating agent or as an adjunct to other modes of treatment used in a multidisciplinary approach. The Nalu Neurostimulation System for PNS is not intended to treat pain in the craniofacial region. Trial devices are only used for trial stimulation (≤ 30 days) to determine effectiveness before recommending a permanent (long-term) device.

Nalu, the Nalu logo, nPower, and the “designed to be more” slogan are registered trademarks of Nalu Medical, Inc.

Media Contact

Jon RuaisNalu Medical, Inc., (760) 448-2360, [email protected]

SOURCENalu Medical, Inc.

About Clara Barnard

Check Also

The future of artificial intelligence in manufacturing industries

Artificial intelligence (AI) is transforming the manufacturing industry. AI can expand the scope of potential …